The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.
WisdomTree BioRevolution ETF WDNA
Morningstar’s Analysis WDNA
Will WDNA outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 22.1
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Novonesis AS Class B | 2.65 | 61,511 | Basic Materials |
Twist Bioscience Corp | 2.55 | 59,314 | Healthcare |
Blueprint Medicines Corp | 2.38 | 55,374 | Healthcare |
Iovance Biotherapeutics Inc | 2.38 | 55,362 | Healthcare |
Natera Inc | 2.13 | 49,526 | Healthcare |
Eli Lilly and Co | 2.12 | 49,216 | Healthcare |
Vericel Corp | 2.08 | 48,323 | Healthcare |
Geron Corp | 2.07 | 48,174 | Healthcare |
Fate Therapeutics Inc | 2.01 | 46,739 | Healthcare |
Agios Pharmaceuticals Inc | 1.72 | 40,049 | Healthcare |